Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY PULMONARY DISEASE
Document Type and Number:
WIPO Patent Application WO/2021/085252
Kind Code:
A1
Abstract:
The present invention provides a medicine for an inflammatory pulmonary disease that is capable of effectively preventing and/or treating an inflammatory pulmonary disease. More specifically, the present invention pertains to a prophylactic and/or therapeutic agent for an inflammatory pulmonary disease that comprises, as an active ingredient, an antibody or an antibody fragment having an antigen-binding activity to an S100A8/A9 heterodimer. Inflammatory pulmonary diseases can be effectively prevented and/or treated by blocking interactions between S100A8/A9 and receptors thereof. More specifically, inflammatory pulmonary diseases can be effectively prevented and/or treated by blocking an interaction between S100A8/A9 and RAGE which is a receptor thereof and thus inhibiting the expression of NF-κB, which is a transcription factor in the downstream of RAGE and induces the expression of various inflammatory cytokines, and, at the same time, inhibiting the proliferation of activated fibroblasts and inhibiting the differentiation of the activated fibroblasts into myofibroblasts. In addition, the prophylactic and/or therapeutic agent for an inflammatory pulmonary disease according to the present invention is appropriately usable as a prophylactic and/or preventive agent for COVID-19 too.

Inventors:
SAKAGUCHI MASAKIYO (JP)
TOYOOKA SHINICHI (JP)
KINOSHITA RIE (JP)
ARAKI KOTA (JP)
Application Number:
PCT/JP2020/039460
Publication Date:
May 06, 2021
Filing Date:
October 20, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NAT UNIV CORPORATION OKAYAMA UNIV (JP)
International Classes:
A61K39/395; A61P11/00; A61P29/00; A61P43/00; C07K16/18
Domestic Patent References:
WO2015177367A12015-11-26
WO2017061354A12017-04-13
Foreign References:
JP2019197222A2019-11-14
Other References:
G. HARDISTY, S. LAW, J. GILLAN, E. G. FINDLAY, S. VERMEREN, D. DAVIDSON, R. GRAY: "WS08-1 Calprotectin: the cystic fibrosis antigen regulates neutrophil migration during experimental lung inflammation and is a novel therapeutic target in cystic fibrosis", JOURNAL OF CYSTIC FIBROSIS, vol. 18, no. Suppl.1, 31 January 2019 (2019-01-31), pages S14, XP055822768
KINOSHITA, R. ET AL.: "Newly developed anti- S 100A8 /A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis", INT J CANCER, vol. 145, no. 2, 31 July 2019 (2019-07-31), pages 569 - 575, XP055646105, DOI: 10.1002/ijc.31982
EHLERMANN PHILIPP; EGGERS KAI; BIERHAUS ANGELIKA; MOST PATRICK; WEICHENHAN DIETER; GRETEN JOHANNES; NAWROTH PETER P; KATUS HUGO A;: "Increased proinflammatory endothelial response to S 100A8 /A9 after preactivation through advanced glycation end products", CARDIOVASC DIABETOLOGY, vol. 5, 2006, XP021017756, DOI: 10.1186/1475-2840-5-6
GAGANDEEP KAUR, GIUSEPPE LUNGARELLA & IRFAN RAHMAN: "SARS-CoV-2 COVID-19 susceptibility and lung inflammatory 14 storm by smoking and vaping", JOURNAL OF INFLAMMATION, vol. 17, 21, 10 June 2020 (2020-06-10), pages 1 - 8, XP055822778
LI MA ET AL., INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 40, 2017, pages 31 - 38
MARGARITOPOULOS ET AL., BMC PULMONARY MEDICINE, vol. 18, 2018, pages 177
LUTZ WOLLINL ET AL., EUROPEAN RESPIRATORY JOURNAL, 2015
FUTAMI J ET AL., BIOCHEM BIOPHYS REP., vol. 19, no. 6, 2016, pages 94 - 100
Attorney, Agent or Firm:
SHOJI, Takashi et al. (JP)
Download PDF: